We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
26
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$60.8M 0.39%
1,787,807
– –
INSM icon
27
Insmed
INSM
$27.5B
$60.4M 0.39%
2,077,601
+225,619
+12% +$5.85M
KOD icon
28
Kodiak Sciences
KOD
$2.41B
$59.7M 0.38%
9,145,115
– –
KNSA icon
29
Kiniksa Pharmaceuticals
KNSA
$6.17B
$54.2M 0.35%
3,000,000
– –
MYOK
30
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$52.8M 0.34%
1,016,306
+701,063
+222% +$32.3M
DBVT
31
DBV Technologies
DBVT
$914M
$42.5M 0.27%
550,956
– –
QURE icon
32
uniQure
QURE
$3.36B
$36.1M 0.23%
605,000
– –
NGNE icon
33
Neurogene
NGNE
$773M
$29.5M 0.19%
546,708
– –
ZYME icon
34
Zymeworks
ZYME
$2.05B
$27.6M 0.18%
1,708,472
– –
KRYS icon
35
Krystal Biotech
KRYS
$10.3B
$25.8M 0.17%
784,674
– –
RARX
36
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$18.4M 0.12%
823,113
– –
MRUS
37
DELISTED
Merus
MRUS
$17.1M 0.11%
1,160,014
– –
AXSM icon
38
Axsome Therapeutics
AXSM
$10.9B
$17.1M 0.11%
+1,200,000
New +$11.1M
AIMT
39
DELISTED
Aimmune Therapeutics
AIMT
$15.1M 0.1%
673,908
– –
CPRX
40
DELISTED
Catalyst Pharmaceutical
CPRX
$14.8M 0.09%
2,900,000
– –
SYRE icon
41
Spyre Therapeutics
SYRE
$9.39B
$13.8M 0.09%
68,544
– –
XNCR icon
42
Xencor
XNCR
$2.07B
$13.3M 0.09%
428,120
-12,066
-3% -$401K
ACGN
43
DELISTED
Aceragen Inc
ACGN
$12.3M 0.08%
284,984
+215
+0.1% +$10.4K
DERM
44
DELISTED
Dermira, Inc.
DERM
$12.3M 0.08%
+906,943
New +$7.56M
MRKR icon
45
Marker Therapeutics
MRKR
$23.2M
$9.9M 0.06%
150,000
– –
SGMO
46
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.54M 0.06%
999,823
– –
ABEO icon
47
Abeona Therapeutics
ABEO
$348M
$9.48M 0.06%
51,529
-32,598
-39% -$5.83M
BLCM
48
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$9.02M 0.06%
267,782
– –
ANAB icon
49
AnaptysBio
ANAB
$1.71B
$8.26M 0.05%
113,086
– –
ALBO
50
DELISTED
Albireo Pharma Inc
ALBO
$8.05M 0.05%
250,000
– –
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2019 Portfolio in Review

As of Q1 2019, Julian Baker held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Julian Baker added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Julian Baker's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Julian Baker fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Julian Baker's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Julian Baker opened 7 new positions and closed 4 in Q1 2019.
  • Julian Baker's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.